Lysophosphatidylcholine and amide as metabolites for detecting Alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 10, 2014, Pages 954-963

  Cui, Yu ^a   Liu, Xiuqin ^a   Wang, Maoqing ^a   Liu, Liyan ^a   Sun, Xiaohong ^a   Ma, Lan ^a   Xie, Wei ^a   Wang, Chao ^a   Tang, Sisi ^a   Wang, Decai ^a   Wu, Qunhong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer disease; Biomarker; Diagnostic tests; Early cognitive impairment; Metabonomics; Multivariate analysis; UPLCQTOF MS

Indexed keywords

AMIDE; AMINO ACID; BIOLOGICAL MARKER; DONEPEZIL; GALANTAMINE; GLUTAMINE; GLUTAMYLGLYCINE; LYSOPHOSPHATIDYLCHOLINE; PALMITIC ACID; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EARLY INTERVENTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLITE; PHOSPHOLIPID METABOLISM; RECEIVER OPERATING CHARACTERISTIC; URINALYSIS; VALIDATION STUDY; DIAGNOSTIC USE; METABOLISM; METABOLOMICS; PROCEDURES; TANDEM MASS SPECTROMETRY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MALE; METABOLOMICS; TANDEM MASS SPECTROMETRY;

EID: 84913586959     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000116     Document Type: Article

References (41)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005;366:2112-17
2. Zhang ZX, Zahner GE, Román GC, et al. Dementia subtypes in China: Prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol 2005; 62:447-53
3. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;16:1363-71
4. Heber LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 2003;8:1119-22
5. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurol Clin 2007;25:577-609
6. Snowdon DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 1996;275:528-32
7. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-25
8. Nicholson JK, Lindon JC, Holmes E. Metabonomics: Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-89
9. Tang HR, Wang YL. MetabonomicsVA revolution in progress. Prog Biochem Biophys 2006;33:401-17
10. Claudino WM, Quattrone A, Biganzoli L, et al. Metabolomics: Available results, current research projects in breast cancer and future applications. J Clin Oncol 2007;25:2840-46
11. Wikoff WR, Gangoiti JA, Barshop BA, et al. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin Chem 2007;53:2169-76
12. Yap IK, Clayton TA, Tang H, et al. An integrated metabonomic approach to describe temporal metabolic disregulation induced in the rat by the model hepatotoxin allyl formate. J Proteome Res 2006;5:2675-84
13. Bundy JG, Lenz EM, Bailey NJ, et al. Metabonomic assessment of toxicity of 4-fluoroaniline, 3, 5-difluoroaniline and 2-fluoro-4-methylaniline to the earthworm Eisenia veneta (Rosa): Identification of new endogenous biomarkers. Environ Toxicol Chem 2002;21:1966-72
14. Liu LY, Li Y, Guan CM, et al. Free fatty acid metabolic profile and biomarkers of isolated post-challenge diabetes and type 2 diabetes mellitus based on GC-MS and multivariate statistical analysis. J Chromatogr B 2010;878:2817-25
15. Chen WX, Lou HY, Zhang HP, et al. Metabonomic characterization of the low-grade human astrocytomas and meningiomas using magic-angle spinning 1H nuclear magnetic resonance spectroscopy and principal component analysis. Prog Biochem Biophys 2006;35:1142-53
16. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMRbased metabonomics. Nat Med 2002;8:1439-44
17. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131: 389-96
18. Wang DC, Sun CH, Liu LY, et al. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: Potential biomarkers of Alzheimer's disease. Neurobiol Aging 2012;33:1057-66
19. McKhann G, Drachma D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
20. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000;45:23-41
21. Ross BM, Moszczynska A, Erlich J, et al. Phospholipid-metabolizing enzymes in Alzheimer's disease: Increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem 1998;70: 786-93
22. Phan VH, Herr DR, Panton D, et al. Disruption of sphingolipid metabolism elicits apoptosis-associated reproductive defects in Drosophila. Dev Biol 2007;309:329-41
23. Kolesnick R. The therapeutic potential of modulating the ceramide/ sphingomyelin pathway. J Clin Invest 2002;110:3-8
24. Yang F, Yan SK, Wang F, et al. DNA immunization perturbs lipid metabolites and increases risk of atherogenesis. J Proteome Res 2008;7: 741-48
25. Han X, M Holtzman D, McKeel DW Jr, et al. Substantial sulfatide deficiency. J Neurochem 2002;82:809-18
26. Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007;36:68-74
27. van der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002;26:317-46
28. Martín-Moreno AM, Reigada D, Ramírez BG, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease. Mol Pharmacol 2011;79:964-73
29. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's diseaseVEpidemiological evidence. Acta Neurol Scand Suppl 2006;185: 50-57
30. Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol 2005;4:841-52
31. Ramsdel HS, Tanak K. Gas chromatographic retention indices of twenty metabolically important acylglycines as trimethylsilyl derivatives. J Chromatogr 1980;181:90-94
32. Aliev G, Smith MA, Obrenovich ME, et al. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotox Res 2003;5:491-504
33. Aliev G, Seyidova D, Neal ML, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci 2002;977:45-64
34. Traina G, Bernardi R, Cataldo E, et al. In the rat brain acetyl-l-carnitine treatment modulates the expression of genes involved in neuronal ceroid lipofuscinosis. Mol Neurobiol 2008;38:146-52
35. Gavrilova SI, Kalyn IaB, Kolykhalov IV, et al. Acetyl-l-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia. Zh Nevrol Psikhiatr Im S S Korsakova 2011;111:16-22
36. Mancuso C, Bates TE, Butterfield DA, et al. Natural antioxidants in Alzheimer's disease. Expert Opin Investig Drugs 2007;16:1921-31
37. ErezA, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am J Med Genet C Semin Med Genet 2011;157: 45-53
38. Wu CC, Singh P, Chen MC, et al. L-Glutamine inhibits beta-aminobutyric acid-induced stress resistance and priming in Arabidopsis. J Exp Bot 2010;6:995-1002
39. Revett TJ, Baker GB, Jhamandas J, et al. Glutamate system, amyloid A peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 2013;37: 6-23
40. Sawada S, Yamamoto C. Gamma-D-glutamylglycine and cis-2, 3-piperidine dicarboxylate as antagonists of excitatory amino acids in the hippocampus. Exp Brain Res 1984;55:351-58
41. Nilsen LH, Witter MP, Sonnewald U. Neuronal and astrocytic metabolism in a transgenic rat model of Alzheimer's disease. J Cereb Blood Flow Metab 2014;34:906-14